logo
  

Coca-Cola Names CFO John Murphy To Additional Role Of President

Beverage company Coca-Cola Co. (KO) announced Thursday that John Murphy will become president and chief financial officer, effective October 1. Murphy, who currently serves as executive vice president and CFO, will add the president role following the retirement of Brian Smith.

The company is evaluating its future plans for the chief operating officer role. The company's operating unit presidents will report to Chairman and CEO James Quincey on an interim basis.

Smith, 66, has served as president and chief operating officer since 2019 following two years as president of the company's former Europe, Middle East and Africa Group. Prior to that role, Smith was group president of Latin America from 2013 to 2016.

Smith joined Coca-Cola in 1997 as Latin America group manager for mergers and acquisitions. He will remain with the company as a senior executive through February 2023.

Murphy, 60, has served as CFO since 2019. He oversees Mergers & Acquisitions, Investor Relations, Global Strategy, Tax, Treasury, Audit, Accounting and Controls, Reporting and Analysis, Real Estate and Risk Management. He began his career at Coca-Cola in 1988 as an international internal auditor.

As president and CFO, he will take on expanded duties, including oversight of Global Ventures; Platform Services; online-to-offline (O2O) digital transformation; and customer and commercial leadership.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT